source
- UniQure files FDA priority review request for Huntington’s gene therapy AMT-130UniQure, a Dutch biotech, announced on Wednesday that it has submitted applications to the U.S. Food and Drug Administration seeking a priority review for its gene therapy AMT-130, which targets th…
- Teva reports positive mid-stage results for celiac disease antibody, BioMarin settles patent fight with AscendisTeva said its experimental antibody TEV-408 showed statistically significant and clinically meaningful reduction in gluten-induced intestinal damage in a mid-stage trial for celiac disease. The tr…